New Treatment Options for Advanced Melanoma

Published Online: Wednesday, September 26, 2012
Follow Pharmacy_Times:
In this video from Memorial Sloan-Kettering Cancer Center, several experts discuss new treatments for melanoma, including vemurafenib (Zelboraf), which targets the activity of mutated BRAF genes found in approximately half of melanoma tumors, and ipilimumab (Yervoy), which uses the immune system to fight melanoma. The participants in the discussion include Paul Chapman, MD, an oncologist and melanoma expert, and Charlotte Ariyan, MD, PhD, a surgeon specializing in surgical oncology who conducts research into immunotherapy for cancer.

Related Articles
Community pharmacists play a significant role in helping patients to maintain the health of their skin.
The FDA has approved Merck’s Keytruda injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following administration of ipilimumab and, if positive for the BRAF V600 mutation, a BRAF inhibitor.
Despite advances in pain management and palliative care, intractable cancer pain remains a significant clinical, social, and financial burden in treating the oncologic population.
Keytruda, manufactured by Merck, is indicated for treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and a BRAF inhibitor.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$